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Abstract
We have previously shown that during pregnancy the E-twenty-six (ETS) transcription factor ELF5 directs the differentiation
of mammary progenitor cells toward the estrogen receptor (ER)-negative and milk producing cell lineage, raising the
possibility that ELF5 may suppress the estrogen sensitivity of breast cancers. To test this we constructed inducible models of
ELF5 expression in ER positive luminal breast cancer cells and interrogated them using transcript profiling and chromatin
immunoprecipitation of DNA followed by DNA sequencing (ChIP-Seq). ELF5 suppressed ER and FOXA1 expression and
broadly suppressed ER-driven patterns of gene expression including sets of genes distinguishing the luminal molecular
subtype. Direct transcriptional targets of ELF5, which included FOXA1, EGFR, and MYC, accurately classified a large cohort of
breast cancers into their intrinsic molecular subtypes, predicted ER status with high precision, and defined groups with
differential prognosis. Knockdown of ELF5 in basal breast cancer cell lines suppressed basal patterns of gene expression and
produced a shift in molecular subtype toward the claudin-low and normal-like groups. Luminal breast cancer cells that
acquired resistance to the antiestrogen Tamoxifen showed greatly elevated levels of ELF5 and its transcriptional signature,
and became dependent on ELF5 for proliferation, compared to the parental cells. Thus ELF5 provides a key transcriptional
determinant of breast cancer molecular subtype by suppression of estrogen sensitivity in luminal breast cancer cells and
promotion of basal characteristics in basal breast cancer cells, an action that may be utilised to acquire antiestrogen
resistance.
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Introduction
The molecular subtypes of breast cancer are distinguished by
their intrinsic patterns of gene expression [1] that have been
refined to become prognostic tests under evaluation or in use [2].
Improving our understanding of the molecular events specifying
these subtypes offers the hope of new predictive and prognostic
markers, development of new therapies, and interventions to
PLOS Biology | www.plosbiology.org 1 December 2012 | Volume 10 | Issue 12 | e1001461
overcome resistance to existing therapies. The estrogen receptor
(ER)positive luminal subtypes are characterized by patterns of
gene expression driven by the combined direct and indirect
transcriptional influences of ER and FOXA1 [3].
ELF5, also known as ESE2 [4] is a member of the epithelium
specific (ESE) subgroup of the large E-twenty-six (ETS)
transcription factor family [5], found in lung, placenta, kidney,
and most prominently in the breast especially during pregnancy
and lactation [6–8]. Placentation fails in Elf5 knockout mice [9]
because de novo production of ELF5 acts with CDX2 and
EOMES to specify and maintain commitment to the trophoblast
cell lineage [10]. The early embryo continues to repress Elf5
expression in association with promoter methylation [11]. In the
developing mammary epithelium Elf5 is re-expressed in a
mutually exclusive pattern with ER [12]. Elf52/2 mice
produced via tetraploid embryonic stem cell rescue [12] or
conditional knockout [13] showed complete failure of mammary
alveolargenesis, a developmental stage driven by prolactin and
progesterone. These hormones induce Elf5 expression and re-
expression of Elf5 in prolactin receptor knockout mammary
epithelium rescued alveolargenesis [14]. Forced ELF5 expression
in nulliparous mouse mammary gland produced precocious
mammary epithelial cell differentiation and milk protein produc-
tion. This was associated with erosion of the mammary CD61+
progenitor cell population, and conversely, Elf5 knockout caused
accumulation of this population, establishing ELF5 as a key
regulator of cell fate decisions made by this progenitor cell
population [12] and explaining the developmental effects
described above.
The CD61+ progenitor cell is the cell of origin for basal breast
cancers [15,16] and Elf5 is expressed predominantly by the ER2
progenitor subset [17], suggesting, together with the developmen-
tal effects of Elf5 outlined above, a role for ELF5 in determining
aspects of molecular subtype of breast cancer. To examine this
hypothesis we manipulated the expression of ELF5 in basal and
luminal breast cancer cell lines and examined the phenotypic
consequences.
Results
ELF5 Expression in Breast Cancer
In the UNC337 breast cancer series [18] ELF5 was expressed
predominantly by the basal subtype in addition to normal breast and
normal-like subtype (Figure 1), an observation confirmed in cohorts
described by Pawitan [19] and Wang [20] (Figure S1). Oncomine
(www.oncomine.org) revealed that ELF5 expression was low in
tumors expressing ER, progesterone receptor (PR), or ERBB2 and
high in the ‘‘triple negative’’ subtype lacking these markers. ELF5
expression was correlated with high grade, poor outcomes such as
early recurrence, metastasis, and death, response to chemotherapy,
and mutations in p53 or BrCa1, all characteristics of the basal
subtypes (Figure S2). ELF5 expression was lower in cancer compared
to patient-matched and micro-dissected normal mammary epithe-
lium (Figure S2), and a series from Sgroi and colleagues [21] found
ELF5 was one of the most consistently downregulated genes at all
stages of breast carcinogenesis (Figure S1).
An Inducible Model of ELF5 Expression in Luminal Breast
Cancer Cells
To test the ability of ELF5 to drive estrogen insensitivity we
used ER+ luminal breast cell lines T47D and MCF7 to construct
DOXycycline (DOX)-inducible expression models of ELF5
(Figure S3A). In humans, ELF5 is also known as ESE2 and 2
isoforms exist. The ESE2B isoform was expressed at 1,774- and
1,217-fold excess over the ESE2A isoform in MCF7 and T47D,
respectively (Figure S3B). We tagged ESE2B at its C-terminus with
V5 (referred to subsequently as ELF5-V5), and demonstrated that
this did not alter its ability to induce the transcription of its best
characterized direct transcriptional target, whey acidic protein
(Wap) in HC11 cells (Figure S3C).
Investigation of the Transcriptional Response to ELF5-V5
We interrogated our inducible models using Affymetrix arrays.
Functional signatures within these expression profiles were identi-
fied by gene set enrichment analysis (GSEA) [22,23], and were
visualized using the Enrichment Map plug-in for Cytoscape [24].
The original data are available via GEO (GSE30407), and GSEA
and Limma analysis from the corresponding author. Figure 2
displays the GSEA networks derived from the effects of forced ELF5
expression in T47D or MCF7 cells and provides a comprehensive
view of the functional consequences of forced ELF5 expression in
the luminal subtype. Figure S4 provides the complete network as a
fully scalable PDF allowing the identification of all nodes. Acute
forced ELF5 expression caused enhancement (positive enrichment-
red nodes) of oxidative phosphorylation, translation, proteasome
function, and mRNA processing. We observed suppression
(negative enrichment-blue nodes) of the DNA synthetic and mitotic
phases of the cell cycle, intracellular kinase signaling, cell
attachment, the transmembrane transport of small molecules,
transcription, and a large set of genes involved in aspects of cancer,
stem cell biology, and especially the distinction of breast cancer
subtypes and estrogen sensitivity. The cancer-proliferation and
breast cancer subtype sub networks, the subjects of further
investigation, are shown in Figures S5 and S6, and the expression
of the individual genes forming the leading edges of example sets
from these clusters are shown as heat maps in Figures S7, S8, S9,
S10. We validated these findings using human breast cancers. Using
luminal A breast cancers from the UNC337 series we produced a
ranked gene list by Pearson correlation with ELF5 expression. This
approach produced an enrichment map that was very similar to that
produced above (Figure 2) by forced ELF5 expression, with cell
cycle sets, cancer sets, and sets describing luminal characteristics
Author Summary
The molecular subtypes of breast cancer are distinguished
by their intrinsic patterns of gene expression and can be
used to group patients with different prognoses and
treatment options. Although molecular subtyping tests are
currently under evaluation, some of them are already in
use to better tailor therapy for patients; however, the
molecular events that are responsible for these different
patterns of gene expression in breast cancer are largely
undefined. The elucidation of their mechanistic basis
would improve our understanding of the disease process
and enhance the chances of developing better predictive
and prognostic markers, new therapies, and interventions
to overcome resistance to existing therapies. Here, we
show that the transcription factor ELF5 is responsible for
much of the patterning of gene expression that distin-
guishes the breast cancer subtypes. Additionally, our data
suggest that ELF5 may also be involved in the develop-
ment of resistance to therapies designed to stop estrogen
stimulation of breast cancer. These effects of ELF5 appear
to represent a partial carryover into breast cancer of its
normal role in the mammary gland, where it is responsible
for the development of milk-producing structures during
pregnancy.
Elf5 in Breast Cancer
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and estrogen responsiveness prominent among the suppressed gene
clusters (Figure S11), demonstrating a very similar action of
endogenous ELF5 in luminal A breast cancers compared to forced
ectopic expression in luminal breast cancer cells.
Identification of ELF5 DNA Binding Sites by ChIP-Seq
We used a mixture of antibodies against V5 and ELF5 to
immunoprecipitate DNA bound by ELF5-V5 in T47D cells,
which we then sequenced, allowing us to map the ELF5-bound
regions of the human genome and to identify the direct
transcriptional targets of ELF5. Intersection of MACS and
SWEMBL peak calls [25,26] identified 1,763 common sites of
ELF5 interaction in the genome at 48 h. Data are available in
Table S1 or via GEO (GSE30407). DNA binding was much
higher at 48 h than 24 h (Figure 3A), consistent with the observed
changes in gene expression by Affymetrix arrays. Combination of
the Affymetrix expression and chromatin immunoprecipitation of
DNA followed by DNA sequencing (ChIP-Seq) data showed that
ELF5 binding within 10 kb of a transcription start site (TSS)
changed the expression level of that gene to a much greater extent
than expected by chance (Figure 3B), demonstrating that ELF5
has consistent transcriptional activity via association with DNA
within this range. ELF5 bound mostly to distal intragenic regions
of the genome (50%) and to introns within genes (25%), but also at
high frequency to promoter regions (20%) mostly within 1 kb of a
TSS (18%). Downstream (Dstr) sites were seldom used. The 59
UTR was also a frequent target of ELF5 but the 39 UTR was
infrequently targeted (Figure 3C). Transcription factor motifs
(Figure 3D) contained within the DNA fragments precipitated by
ELF5 were predominantly ELF5 and other ETS factor motifs;
however, we also observed enrichment of sites for Stat1 and Stat3,
which contain a TTCC core ets motif. We also observed very
significant enrichment of sites for the FOXA1 and NKX3-2
transcription factors. The binding of ELF5 to the FOXA1
promoter region is shown in Figure 3E. We validated the
indicated peak on the FOXA1 promoter, and three other target
transcription factors by ChIP-qPCR (Figure 3F). FOXA1, RUNX1,
GATA3, and MEIS2 were validated as targets of ELF5 by
comparison to input, indicating that ELF5 heads a transcriptional
cascade. We searched for curated functional signatures among the
ChIP targets using GSEA (Figure 3G). Many of the functional
signatures observed in the ChIP data were also present in the
expression data, demonstrating a direct transcriptional action of
ELF5 to exert these regulatory effects.
The Effect of ELF5 on Breast Cancer Cell Accumulation
We examined changes in phenotype observed in T47D-ELF5-
V5 and MCF7-ELF5-V5 cells following DOX treatment. In
control T47D and MCF7 cells carrying the puromycin-resistant,
but otherwise empty expression vector, normal logarithmic
accumulation of cells during culture continued with or without
DOX (Figure 4A). In contrast, when ELF5-V5 was induced
(denoted as T47D-ELF5-V5 and MCF7-ELF5-V5), cells stopped
accumulating between 24 and 48 h after DOX administration
(Figure 4B), regardless of the timing of induction (Figure S12A).
The 4-fold induction of ELF5-V5 expression by DOX in T47D
cells was similar to that produced for endogenous ELF5 with
R5020, a synthetic progestin (Figure S12A, inset), demonstrating
that this model produces physiological increases of ELF5
expression. The effect was also reversible (Figure S12B). Investi-
gation of anchorage-independent growth in soft agar showed that
induction of ELF5-V5 produced fewer colonies (Figure S12C).
Xenografts of T47D-ELF5-V5 cells in nude mice grew at a slower
rate when mice received DOX (Figure 4C).
Figure 1. ELF5 expression in normal breast and breast cancer. ELF5 expression in the UNC337 breast cancer cohort according to subtype. Top
panel shows combined results with statistical analysis (thick black line, median;, box, interquartile range 25%–75% of points; whiskers, 1.56
interquartile range; crosses, individual tumors). Bottom panel ELF5 expression in all individual tumor and normal samples. Basal and normal had
significantly higher expression of ELF5.
doi:10.1371/journal.pbio.1001461.g001
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Knockdown of ELF5 expression by more than 80% had a small
effect on total cell accumulation in T47D or MCF7 cells (Figure
S12D). We knocked down ELF5 in two basal breast cancer cell
lines and observed a significant and sustained reduction in cell
accumulation rate (Figure 4D and 4E), which was not seen in
luminal cells (Figure S12D). This observation clearly demonstrates
a subtype-specific role of ELF5 in breast cancer cells.
Cells can fail to accumulate in culture via two main mechanisms,
by reduced rates of cell division or by the loss of cells through
detachment and apoptosis. We investigated these possibilities.
Figure 2. Visualization of the transcriptional functions of ELF5 in breast cancer. Affymetrix transcript profiling following induction of ELF5
in T47D and MCF7 luminal breast cancer cells, analysed by LIMMA and GSEA. Results are visualized using the enrichment map plug-in for Cytoscape.
Each circular node is a gene set with diameter proportional to the number of genes. The outer node color represents the magnitude and direction of
enrichment (see scale) in T47D cells, inner node color enrichment in MCF7 cells. Thickness of the edges (green lines) is proportional to the similarity of
gene sets between linked nodes. The most related clusters are placed nearest to each other. The functions of prominent clusters are shown. The
network can be examined in detail using the scalable PDF in Figure S4.
doi:10.1371/journal.pbio.1001461.g002
Elf5 in Breast Cancer
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We examined cell proliferation. Labeling of cells with BrdU and
propidium iodide showed that induction of ELF5-V5 caused
repartitioning of cells from S-phase into gap 1 of the cell cycle (G1)
(Figure S13A). Western blotting showed a loss of phosphorylated
forms of the pocket proteins, p130, p107, and Rb, accompanied by
loss of cyclin proteins A2, B1, and D1, and accumulation of the
inhibitor p21 (Figure S13B). Many of these changes also occurred
at the mRNA level (Figure S13C), indicating a transcriptional
basis to these changes that together suggest inhibition of
proliferation by G1 arrest. To test this we arrested T47D-ELF5-
V5 cells in the G1 phase of the cell cycle using hydroxyurea (HU)
and then released them, by HU wash out, into cycle in the
presence and absence of induction of ELF5-V5 expression
(Figure 4F, corresponding flow cytometric plots in Figure S13D,
and Western blot quantification in Figure S13E). Induction of
ELF5-V5 reduced the percentage of cells exiting G1 into S-phase
and was associated with a reduced accumulation of cyclin D1
protein and reduction in the expression of cyclin B1, demonstrat-
ing that ELF5-V5 expressing cells failed to re-enter the cell cycle
from G1.
We previously formed a set of 641 genes associated with cell
cycle control by a combination of genes from cell cycle–related
GO ontologies [27]. This set very significantly overlapped with
125 genes repressed, and 42 genes induced, by ELF5 expression
(Figure S14A), and of these 55 were ELF5 ChIP targets (Figure
S14A, Figure S14B heat maps) indicating a direct transcriptional
influence of ELF5 on proliferation. Upregulated ELF5 ChIP
targets were characterized by the presence of tumor suppressor
genes while downregulated genes were enriched in genes
controlling cell proliferation. Upregulated genes included
RB1CC1 (promotes RB1 expression), TBRG1 (promotes G1
arrest via CDKN2A), IRF1 (initiates interferon response), COPS2
(p53 stabilizer), CHFR (prevents passage into mitosis), DAB2 (lost
in ovarian cancer), and RAD50 (DNA damage checkpoint). Also
in this group are DDIT3 (promotes apoptosis due to endoplasmic
reticulum stress) and ERBB2IP (disrupts RAF/RAS signaling).
ELF5 ChIP targets repressed by elevated ELF5 were characterized
by genes required for mitosis, such as GTSE1 (microtubule
rearrangement), KIF11 (spindle formation), FBXO3 (anaphase
promoting complex), KNTC1 (mitotic check point), PPP1CC
(PTW/PP1 complex member), and PMF1 (MIS12 complex
chromosome alignment). Other proproliferative ELF5 ChIP
targets that were downregulated include EGFR and IGF1R
(potent mammary mitogen receptors), MAPK13 (downstream
signaling molecule), c-MYC (key regulator of proliferation),
KLF10 (transcriptional repressor of proliferation), and NME1
and SLC29A2 (required for nucleotide synthesis). This 55-gene
signature is significantly enriched in many breast cancer series
(Figure S14C) and showed differential expression between ER+
and ER2 cancers (Figure S14B, right-hand heat map). Interest-
ingly the mitogenic genes that are repressed by forced ELF5
expression in ER+ T47D cells are generally highly expressed in
ER2 cancers (Figure S14B), showing again that ELF5 has a
subtype-dependent role in cell proliferation and may contribute to
the proliferative drive in ER2 cancers.
A large number of detached and floating cells were observed in
cultures after 48 h of DOX treatment and became most
prominent by 72 h (Figure 5A). Replating efficiency was greatly
reduced, indicating that new adherence proteins could not be
rapidly synthesized and deployed following their destruction with
trypsin (Figure 5B). Higher rates of apoptosis, measured using flow
cytometry, were observed in T47D-ELF5-V5 and MCF7-ELF5-
V5 cells (Figure 5C). The levels of beta 1-integrin were much lower
by 72 h (Figure 5D quantitated in Figure S12E and S12F). Its
signaling partner integrin-linked kinase (ILK) also showed reduced
expression. Focal adhesion kinase (FAK) levels also fell slightly but
phosphorylation of FAK was much reduced from 5 d, as was SRC
kinase expression and especially phosphorylation, indicating
reduced signal transduction in response to the lower levels of
beta1-integrin and detection of the extracellular matrix. Together
these results implicate loss of extracellular integrins in the
detachment of cells in response to forced ELF5 expression.
ELF5 Modulates Estrogen Action
Among the direct transcriptional targets of ELF5 are a number
with established roles in proliferation in response to estrogen, such
as FOXA1, MYC, CDK6, FGFR1, and IGF1R (Table S1). In
addition, key genes associated with the estrogen-sensitive pheno-
type, such as ESR1 and estrogen-response genes, such as GREB1
and XBP1, are downregulated (Figure S9). Western blotting
showed that induction of ELF5-V5 expression caused falls in the
levels of ER, the estrogen-induced gene progesterone receptor
(PGR), pioneer factor FOXA1, and progenitor cell-regulator
GATA3 (Figure 6A). The activities of ER and FOXA1 transcrip-
tional reporters (ERE and UGT2B17, respectively) also fell
(Figure 6B), demonstrating that forced ELF5 expression sup-
pressed estrogen sensitivity. These cell lines are dependent on
estrogen for proliferation, raising the possibility that forced ELF5
expression inhibited proliferation simply by reducing ER expres-
sion. We tested this possibility by forced re-expression of ER and
treatment with estrogen (Figure 6C), but we did not observe any
relief of the inhibition of proliferation caused by forced ELF5
expression.
We further examined the effects of induction of ELF5 on
estrogen-driven gene expression by intersecting our ELF5-
regulated genes with a previously defined set of estrogen-regulated
genes in MCF7 cells [27]. Among a set of 477 genes showing
estrogen-induced expression in MCF7 cells (Figure 6D, ‘‘E2
induced’’), 115 showed loss of expression in response to ELF5-V5,
an overlap with a highly significant p-value (p= 5E284) and odds
ratio (OR = 16). These genes (heat map in Figure S14D, ‘‘E2I’’),
contained signatures for cell cycle control and DNA replication
gene sets. Furthermore when we focused on 71 estrogen-induced
genes previously defined as involved in proliferation [27]
(Figure 6D, ‘‘E2 Prolif’’), we observed the same very significant
enrichment (p= 2E232), confirming the action of ELF5 to repress
Figure 3. Chromatin immunoprecipitation and sequencing to identify genomic ELF5 binding sites. (A) Conservative analysis of the ChIP-
Seq identified 1,763 peaks of ELF5 interaction with the genome at 48 h of DOX treatment, with a smaller number seen at 24 h. Relationship between
enrichment and distance from binding peak is shown. (B) relationship between change in gene expression with 48 h of DOX treatment and distance
of a peak of ELF5 DNA binding from the TSS. Blue area defines the region of random chance computed by multiple random assignments of the ChIP
data to gene expression. Red line shows the actual relationship between a peak’s distance from the nearest gene’s TSS and its change in expression in
response to ELF5-V5 induction. (C) ELF5 binding within the indicated genomic regions. (D) The number of genomic transcription factor binding
motifs (TRANSFAC) found in the ChIP fragments relative to their enrichment. (E) example of an enriched peak of ELF5-V5 binding to DNA (FOXA1
gene). (F) ChIP-qPCR validation of ELF5 binding sites to transcription factor gene promoters. I, IgG control antibody IP, E, ELF5 antibody IP, for the
indicated PCR targets at 24 and 48 h; * significant (p,0.05) enrichment against input; # significant enrichment against RND3 control gene; D
significant 24 h versus 48 h. (G) GSEA of curated functional sets among ELF5 ChIP targets.
doi:10.1371/journal.pbio.1001461.g003
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the expression of estrogen-induced genes involved in proliferation.
The effect of ELF5 expression on 289 estrogen-repressed genes
(Figure 6D, ‘‘E2 repressed’’ and heat map Figure S14D, ‘‘E2R’’)
was much less pronounced. Thus the predominant effect of forced
ELF5 expression was suppression of estrogen-induced gene
expression. Just 29 genes were direct transcriptional targets of
both ELF5 and ER, a small fraction of the total number of genes
showing changed expression, indicating that the actions of ELF5
and ER are largely executed by intermediaries, rather than direct
action of ELF5 and ER at the same genomic locus.
We used hypergeometric enrichment to discover previously
defined experimental signatures among the direct transcriptional
targets of ELF5. Signatures indicative of estrogen action were
prominent among ELF5 ChIP targets downregulated (fold change
[FC].1.5 and false discover rate [FDR].0.25) by ELF5
expression, including sets of genes that were ESR1 targets,
involved in endocrine resistance or which distinguished the
luminal from basal subtypes (Figure 6E). Among the cancer-
focused sets provided by Oncomine (set names in lower case in
Figure 6E) were many associated with distinction of the triple
negative and ER/PR/HER2-positive subtypes. Sets among the
upregulated ChIP targets included metastasis, apoptosis, and high
grade. Heat maps illustrating the changed expression of the
individual ELF5 ChIP targets are shown using the top-hit breast
cancer series (* marked sets in Figure 6E shown as heat maps in
Figure S14E). This investigation again illustrates the repression of
estrogen action by induction of ELF5, but indicates that many of
the poorer prognostic aspects of the ER2 subtypes may be due to
ELF5-induced genes. Again ELF5 appears to have subtype-
specific actions.
ELF5 Specifies Breast Cancer Subtype
We examined the ability of the direct transcriptional targets of
ELF5 to predict aspects of breast cancer phenotype. A set of 164
genes was defined as ChIP targets with altered expression in
response to induction of ELF5 in T47D cells. This gene set
accurately predicted ER status (Figure S15A) in the Reyal breast
cancer series [28]. The Confusion Matrix (Figure S15B) shows that
the direct transcriptional targets of ELF5 accurately predicted
intrinsic subtype, with nearly 100% of the luminal/basal
distinctions correctly identified. Clustering of the NKI-295 set
[29], using the direct transcriptional targets of ELF5, distinguished
the intrinsic subtypes and produced a clear separation of tumor
characteristics such as poor prognosis, early metastasis, early
death, recurrence, survival, grade, mutation status, and marker
expression, such as ER and PR (Figure S15C).
We assessed the ability of ELF5 expression to directly alter
molecular subtype using two methods developed for this purpose,
GSEA [30] and expression signature analysis [15] (Figure 7).
Figure 7A shows a cytoscape network of gene sets distinguishing
molecular subtype, which combines data from forced expression of
ELF5 in MCF7 luminal breast cancer cells (node center) with data
from knockdown of ELF5 in HCC1937 basal breast cancer cells
(outer node ring). This is a sub network of the complete cytoscape
network (Figure S16) and the T47D-HCC1937 sub network
(Figure S17) is almost identical. The gene sets clustered into four
groups distinguishing luminal subtype, basal subtype, estrogen
responsiveness, and the mesenchymal phenotype. ELF5 sup-
pressed the mesenchymal phenotype in both luminal and basal
cells, representing a subtype-independent action. In luminal cells
forced ELF5 expression suppressed the luminal subtype and
estrogen-responsive phenotype. In basal cells knockdown of ELF5
expression suppressed the basal subtype, illustrating subtype-
specific actions of ELF5. Figure 7B shows the expression signature
analysis. In HCC1937 cells knockdown of ELF5 produced a very
significant shift in molecular subtype away from the basal subtype
toward the claudin-low and normal-like subtypes, consistent with
the enrichment of the mesenchymal phenotype observed by GSEA
and the suppression of patterns of basal gene expression. In both
luminal cell lines a shift away from the luminal subtype was
observed (Figure 7C and 7D), consistent with the GSEA results. In
MCF7 the shift was toward the basal and Her2+ subtypes and in
T47D toward the normal-like and claudin-low subtypes.
ELF5 Underpins the Acquisition of Antiestrogen
Resistance
Expression studies and ChIP-Seq (Figures 2, 6E, and 7) showed
that ELF5 transcriptionally regulated a number of genes involved
in resistance to antiestrogens. We examined ELF5 expression in
Tamoxifen (TAMR)- [31] or Faslodex (FASR)- [32] resistant cells,
derived from MCF7 cells in Cardiff (MCF7C). Greatly elevated
levels of ELF5 mRNA were observed (Figure 8A) compared to
their parental MCF7C cells, accompanied by loss of expression of
key estrogen response genes. The 164-gene ELF5 transcriptional
signature used to classify subtype in Figure 6 showed a response in
TAMR cells (22 genes significantly suppressed, 24 significantly
induced) and FASR cells (34 genes significantly suppressed, 46
significantly induced). qPCR confirmed the elevation of ELF5
mRNA in TAMR and FASR cells compared to the parental
MCF7 (MCF7C) and MCF7 from the Garvan Institute (MCF7G)
used elsewhere in this study (Figure 8B). When we intersected the
genes from the antiestrogen sets enriched in the expression data in
response to forced ELF5 expression (Figure 2A) with ELF5 ChIP
targets, and asked using Oncomine what drug treatments
produced similar profiles, we found a predominance of signatures
resembling those resulting from inhibition of EGFR (a key
pathway driving Tamoxifen resistance in TAMRs [31]) among
overexpressed genes, and signatures indicative of the IGFR1
pathway and other kinases, or mitosis-disrupting agents, among
under expressed genes (Figure 8C). Both these pathways have been
implicated in the development of resistance to antiestrogens.
Treatment with estrogen greatly reduced ELF5 expression in
MCF7C cells and this effect was blunted in the TAMR cells
(Figure 8D). Knockdown of ELF5 in TAMR cells completely
Figure 4. Elf5 modulates cell adhesion and proliferation of breast cancer cells. T47D (circles) and MCF7 (squares) cells were permanently
transduced with DOX-inducible ELF5-V5 or empty retroviral vectors. Pooled cells were grown with puromycin. Representative experiments are shown.
Bars, standard error of the mean (SEM). (A) Control cells transduced with empty vector grown in the absence of DOX (2D, open symbols) or presence
of DOX from 0 h (+D0 h, closed symbols). (B) Cells transduced with the DOX-inducible ELF5-V5 expression vector grown in the presence of DOX
(+D0 h, closed symbols) or absence of DOX (2D, open symbols). Inset Western blot of ELF5-V5 induction. (C) T47D-ELF5-V5 cells were grown as
xenografts in nude mice, with (+D) or without (2D) DOX supplementation of food. Inset shows induction of ELF5-V5 expression. (D and E) Basal breast
cancer cells HCC1937 (circles, dashed lines) or HCC1187 (squares, solid lines) were transfected with siRNA against ELF5 mRNA (siELF5, solid symbols),
or were mock transfected (open symbols) before quantification of cell number with time. Insets, The degree of ELF5mRNA knockdown was measured
by qPCR at 72 h. (F) Cells were arrested at G1-S phase by treatment with hydroxyurea, then released. Histograms show the subsequent distribution of
cells within the cell cycle phases by PI staining at the indicated times post release, green +DOX, red –DOX, and Western blots show the expression of
key cell cycle regulatory proteins.
doi:10.1371/journal.pbio.1001461.g004
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stopped cell accumulation while in the parental MCF7C little
effect on the rate of increase in cell number was seen (Figure 8E).
ELF5 IHC on TAMR cell pellets confirmed the knockdown.
Measurements of S-phase showed that 25% of TAMR cells and
42% of MCF7C cells were in S-phase of the cell cycle during log-
phase growth, consistent with the known characteristics of these
lines. Knockdown of ELF5 reduced TAMR S-phase by 28%, and
MCF7C S-phase by 12% (Figure 8F), consistent with the observed
effects on cell number. These observations demonstrate that
elevation of ELF5 expression and greatly increased reliance upon it
for cell proliferation is a key event in the acquisition of Tamoxifen
insensitivity.
Taken together, the results in this study show that ELF5 is
involved in the proliferation of breast cancer cells in culture, that
ELF5 suppressed the estrogen-responsive phenotype in luminal
breast cancer cells, and induced aspects of the basal phenotype in
basal breast cancer cells. In both subtypes ELF5 suppressed the
mesenchymal phenotype. ELF5 specified patterns of gene
expression that distinguished the breast cancer subtypes. Signifi-
cantly for clinical management of breast cancer, elevation of ELF5
is a mechanism by which MCF7 cells can become insensitive to
antiestrogen treatment.
Discussion
In this report we show that ELF5 exerts wide transcriptional
effects with functional outcomes on cell proliferation, adhesion, the
molecular determinants of breast cancer subtype and phenotype,
and acquired resistance to Tamoxifen. These outcomes are aspects
of a general specification of an estrogen-insensitive cell fate exerted
through modulation of ER, FOXA1, and other transcriptional
regulators in luminal cells, and the induction of basal character-
istics in basal cells.
Two key factors in determining the luminal phenotype are
FOXA1 and ER. Recent findings show that ER-chromatin
binding and the resulting transcriptional response to estrogens
are dependent on FOXA1 expression and its action as a pioneer
factor for chromatin-ER binding [3]. We show that forced
expression of ELF5 in the luminal context directly represses
FOXA1 expression and transcriptional activity. We also show that
ER expression falls, as does the expression of many estrogen-
responsive genes and ER-driven transcription. This mechanism
allows ELF5 to suppress key aspects of the luminal phenotype,
demonstrated by GSEA and by expression signature analysis. The
resulting loss of proliferation is likely to result from multiple
mechanisms. Although the proliferation of MCF7 and T47D cells
is stimulated by estrogen-driven signaling and transcription, the
loss of ER signaling was not the sole cause of proliferative arrest as
forced ER re-expression did not effect a rescue (Figure 6C).
Rather, ELF5 may act directly to regulate genes controlling cell
proliferation (Figure S14). In addition the loss of beta1-integrin
was observed. Beta1-integrin acts in mammary cells via FAK and
src to induce p21 and cell cycle arrest [33], a mechanism that is
also apparent in our data (Figures 5D and S13C). There are
additional large changes in the expression of many other key
signaling molecules (Figures 2 and S4) that may also act to
suppress proliferation, including EGFR and IGFR signaling.
Finally the changes in metabolic activity, including protein and
RNA synthesis and oxidative phosphorylation are also likely to
impinge on cell proliferation.
Loss of ELF5 expression in the basal subtype HCC1937 cells
resulted in reduced cell proliferation, loss of basal patterns of gene
expression, and a shift toward the mesenchymal phenotype,
demonstrated by the GSEA results and the expression signature
analysis. These results show that ELF5 specifies key characteristics
of the basal phenotype, but also prevents the expression of the
mesenchymal phenotype, as it does in the luminal context. Thus
we can discern both subtype-dependent and -independent effects
of ELF5. The subtype-dependent effects are a likely product of the
differentiation state of the cell and the fate decisions made during
differentiation produced by interactions of the ELF5 regulatory
Figure 5. Elf5 modulates the adhesion of breast cancer cells. (A)
Quantification of detached cells in cultures treated with DOX (+D)
compared to no induction (2D). (B) Ability of DOX-treated cells to
replate 4 h after trypsin destruction of attachment proteins, compared
to untreated cells. Data are expressed as a percentage of replated
untreated cells. (C) Proportion of apoptotic cells in DOX treated (grey
bars) compared to untreated (black bars) T47D-ELF5-V5 cells, measured
by flow cytometry using the M30 antibody. (D) Expression and
activation of key cell adhesion proteins following DOX induction of
ELF5-V5 expression.
doi:10.1371/journal.pbio.1001461.g005
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transcriptional network with other transcriptional regulatory
networks present in the cell, while the independent effects are
likely to result from direct transcriptional actions that lack these
interactions and are thus subtype independent.
We propose that the effects of ELF5 in the breast cancer cell lines
represent a carry over of the normal developmental role of ELF5
into breast cancer (Figure 8G). The primary developmental target
for ELF5 is the mammary progenitor cell population (P), produced
from the stem cell population (S), and which exhibits aspects of the
two cell lineages that it produces (drawn as P cell overlaps). Under
the dominant influence of ELF5 a progenitor cell differentiates to
become an ER2 cell, and with further differentiation and hormonal
stimulation ultimately produces a mature (M) alveolar cell capable
of large-scale milk synthesis. By this process ELF5 establishes the
secretory cell lineage [12]. It is likely that under a dominant estrogen
influence the same progenitor cell differentiates to become an ER+
cell with different functions, such as regulation of the stem and
progenitor hierarchy by paracrine influence. Recent findings
support this mechanism [30]. It is likely that ELF5 and FOXA1
provide the key to the decision made by the progenitor cell. We
hypothesize that the outcome of competing estrogen and ELF5
actions on a precancerous instance of the progenitor cell may play a
significant role in determining the subtype of breast cancer that
results. Additional events may occur subsequent to this decision that
alter ELF5 expression and these may be involved in aspects of
tumor progression, such as the acquisition of insensitivity to
antiestrogens when ELF5 expression increases in the context of
luminal breast cancer, or the acquisition of the mesenchymal
phenotype when ELF5 expression is lost in basal breast cancer.
Some tumors, such as the claudin low subtype, may be innately
mesenchymal, as a result of the oncogenic transformation of late
stem or early progenitor cells that do not yet express ELF5 or
FOXA1 and ER. ELF5 may act to specify epithelial characteristics
during the normal differentiation of the stem cell to become a
progenitor cell. In this context forced ectopic expression of ELF5
may reduce the mesenchymal nature of the claudin low subtype.
We have observed that progestin-induced inhibition of T47D
cell proliferation is accompanied by an increase in ELF5
expression, and that this in turn acts to oppose the inhibitory
action of progestins on cell cycle regulation [34]. A similar effect
may protect some cells from complete growth inhibition by
Tamoxifen, and prime them for later ELF5-driven escape of
antiestrogen therapy. Further increases in ELF5 expression
provide both an alternate source of proliferative signals and
further suppression of sensitivity to ER-mediated signals, produc-
ing a mechanism allowing TAMR cells to escape TAM-induced
growth inhibition. In this scenario the ELF5 ChIP target c-MYC
may provide the proliferative drive. These experiments shed new
light on the process of acquired resistance to antiestrogens,
implicating ELF5 as a potential therapeutic target in antiestrogen-
resistant disease and providing a potential marker predicting the
failure of antiestrogen therapy.
Overall we show that the transcriptional activity of ELF5
suppresses estrogen action in luminal breast cancer, enhances
expression of the basal phenotype, specifies patterns of gene
expression distinguishing molecular subtype, and exerts a prolif-
erative influence that can be modified to allow luminal breast
cancer to become resistant to antiestrogen treatment.
Materials and Methods
Ethics Statement
Mice were maintained following the Australian code of practice
for the care and use of animals for scientific purposes observed by
The Garvan Institute of Medical Research/St. Vincent’s Hospital
Animal Ethics Committee (AEC).
Plasmid Construction, Transfection, Infection, and
Treatment
ESE2B was tagged at the 39 end with V5 and incorporated into
the pHUSH-ProEX vector [35] used as a retrovirus. Transient
transfection used FuGENE (Roche). Puromycin was used at 1 mg/
ml for MCF7-EcoR and 2 mg/ml for T47D-EcoR, DOX at
0.1 mg/ml changed daily, R5020 at 10 nM.
Colony Formation Assays
Colonies were visualized with the Diff Quick Stain Kit (Lab
Aids) or crystal violet. Colony number and size measured with
Image J 1.41o (Wayne Rasband, US National Institutes of Health),
excluding cells ,0.1 mm.
Protein Analysis and Antibodies
Protein lysates (40 mg per lane) were prepared in NuPAGE
LDS Sample Buffer and Sample Reducing Agent and separated
on NuPAGE Bis-Tris acrylamide gels in MOPS buffer or Tris-
Acetate gels run in Tris-Acetate SDS buffer, transferred to
polyvinylidene difluoride membranes (BioRad), blocked with
1% skim milk powder, 50 nM Na3PO4, 50 mM NaCl, and 0.1%
Tween 20 for 1 h, primary antibody for 2 h to overnight, and a
horseradish peroxidase (HRP)-linked secondary antibody for
1 h, with four washes of 50 nM Na3PO4, 50 mM NaCl, and
0.1% Tween 20. Detection by enhanced chemiluminescence
(Perkin-Elmer) on Fuji Medical X-ray Film (Fujifilm). Primary
antibodies used were anti-b-actin (AC-15, Sigma), anti-cyclin B1
(GNS-11, BD), anti-cyclin D1 (DCS6, Novacastra), anti-cyclin E
(HE12, sc-247, Santa Cruz), anti-ELF5/ESE2 (N20, sc-9645,
Santa Cruz), anti-ERa (HC20, sc-543, Santa Cruz), anti-FAK
(3285, Cell Signalling Technologies), anti-ILK (3/ILK, BD),
anti-integrin b1 (18, BD), anti-p21 (70, BD), anti-p27 (C19, sc-
528, Santa Cruz), anti-p107 (C19, sc-318, Santa Cruz), anti-
pFAK (pY397, BD), anti-pRb (554136, BD), anti SRC
(Calbiochem 327), anti pSRC (Cell Signalling 2101), and anti-
V5 (R960-25, Invitrogen). Secondary antibodies were HRP-
donkey anti-goat (Santa Cruz), HRP-donkey anti-rabbit (Amer-
sham Biosciences), and HRP-sheep anti-mouse (Amersham
Biosciences).
Figure 6. ELF5 suppresses the estrogen-sensitive phenotype. (A) Western blot showing reduced expression of key genes involved in the
response to estrogens following induction of ELF5 expression. (B) Reduced transcriptional activity of reporters of ER and FOXA1 (UGT2B17 promoter)
transcriptional activity following induction of ELF5 in MCF7 cells. Black bars, -DOX, grey bars +DOX 72 h for ERE and 24 h and 48 h for FOXA1. (C) Cell
accumulation in MCF7-V5 cell cultures with (+E) or without (2E) 10 nM estrogen treatment, or following expression of ER (+ER) and 10 nM E in the
context of induced ELF5. Black bars, -DOX; grey bars +DOX, 72 h and 144 h, respectively. (D) interaction of ELF5-regulated gene sets with estrogen-
regulated gene sets. p-Values and odds ratios derived from hypergeometric tests. Number of genes in brackets. (E) Enrichment of gene sets in ELF5
ChIP targets either down (Dn) or Up in response to forced ELF5-V5 expression in T47D cells with DOX. P-Values for hypergeometric tests from GSEA
(upper case) or Oncomine (lower case).
doi:10.1371/journal.pbio.1001461.g006
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Figure 7. ELF5 specifies breast cancer subtype. (A) Sub network of breast cancer subtype gene sets derived from forced ELF5 expression in
MCF7 luminal breast cancer cells (inner node color) and knockdown of ELF5 expression in HCC1937 basal breast cancer cells. Node size is
proportional to gene set size; thicker green lines indicate greater gene set overlap. Nodes are positioned according to similarity in gene sets. Labels in
bold type indicate the functional significance of the four clusters generated, label is plain type is the gene set name. The full network is shown in
Figure S16. (B–D) expression signature analysis of the ELF5-induced changes in molecular subtype produced by ELF5 knockdown in HCC1937 cells (B),
or forced ELF5 expression in MCF7 cells (C), or T47D cells (D). Bars show the indicated comparisons that produce the associated p-values. BS,
borderline significance; NS, not significant.
doi:10.1371/journal.pbio.1001461.g007
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Reporter Assays
Reporter plasmids, consensus ERE were a kind gift from
Malcolm Parker (Imperial Cancer Research Fund, London);
FOXA1 responsive UGT2B17/-155ApGL3 a kind gift from Peter
Mackenzie (Flinders University, Australia) [36]; and pRL-TK
(Promega), b-galactosidase a kind gift from Gerald Clesham,
University of Cambridge, Cambridge, UK. Solubilization was in
Passive Lysis Buffer (Promega) and measured with Dual Luciferase
Reporter Assay System (Promega) and Galacto-Light reagents
(Applied Biosystems).
Attachment Assays
Monolayers were detached with 0.25% trypsin, counted, and re-
plated at equal density. Unattached cells were gently removed in
PBS prior to counting with a haemocytometer.
Flow Cytometry
Asychronous cells were pulsed with 10 mM BrdU (Sigma) for
2 h (MCF7 or 20 min (T47D) prior to harvesting. Where
indicated cells were synchronised with 1 mM hydroxyurea
treatment for 40 h. Cells were harvested via trypsinisation, and
fixed in 70% ethanol for 24 h, stained with 10 mg/ml propidium
iodide (Sigma) for 2–5 h, and incubated with 0.5 mg/ml RNase A
(Sigma). Flow cytometry was performed using FACS Calibur or
FACS Canto cytometers (BD Biosciences), and data analysis
performed with FlowJo software (Tree Star Inc.).
Microarray Analysis
Total RNA was extracted with the RNeasy Minikit (Qiagen)
and DNase-treated with the DNase kit (Qiagen). RNA quality was
assessed using a RNA Nano LabChip and Agilent Bioanalyzer
2100. Probe labeling and hybridization to Affymetrix Human
Gene 1.0 ST Gene Arrays was done at the Ramaciotti Centre for
Gene Function Analysis at the University of New South Wales.
Microarrays were normalised using RMA via the NormalizeAffyme-
trixST GenePattern module http://pwbc.garvan.unsw.edu.au/gp.
Differentially expressed genes were detected using Limma, using
positive false discovery rate (FDR) multiple hypothesis test
correction. GSEA (version 2.04) used 1,000 permutations, in
pre-ranked mode, using the t-statistic from Limma to rank each
gene using gene sets from MSigDB version 3.0. Data are available
from GEO with accession number GSE30407.
ChIP-Sequencing Analysis
Cells were fixed in 1% formaldehyde, at 37uC for 10 min,
washed 26with cold PBS, scraped into 600 ml PBS with protease
inhibitors (P8340, Sigma), spun 2 min at 6,000 g, washed as
before, and snap frozen in liquid nitrogen. ChIP-Seq as previously
described [37] using a 50%–50% mixture of V5-specific antibody
and the Santa Cruz N20 anti ELF5 antibody. DNA was processed
for Illumina sequencing using 36-bp reads on a GAIIx. Sequences
were aligned against NCBI Build 36.3 of the human genome using
MAQ (http://maq.sourceforge.net/) with default parameters. The
aligned reads were converted to BED format using a custom script.
ChIP-qPCR used the ABI Prism 7900HT Sequence Detection
System.
Mice
Balb/C Nude mice (Jackson Lab) were used as xenograft hosts.
Breast Cancer Subtype
Potential as classifiers was investigated using the diagonal linear
discriminant analysis (DLDA) or Naı¨ve Bayes classifier, 100
iterations of 10-fold cross-validation (CV) and the misclassification
rate recorded in each instance. Boxplots of ER misclassification
rate were achieved for each of the 1,000 (100 iterations of 10-fold
CV) classifiers built to predict ER status. The confusion matrix
shows as percentages the relationship between true intrinsic
subtype classification, as defined by [1] and [38] and predicted by
the Naı¨ve Bayes classifier. Expression signature analysis [15] and
GSEA [30] to examine changes in subtype was carried out as
described.
Supporting Information
Figure S1 ELF5 expression in the breast cancer molec-
ular subtypes. Top panels. Tumors from the indicated studies
were classified by molecular subtype and their ELF5 expression
level given by the Affymetrix probe set 220625_s_at is graphed.
Similar results were found with the 220624_s_at probes (not
shown) The p-value for differential expression of ELF5 by the basal
subtype is shown. Bottom panel, Redrawn from Ma et al. [21] to
combine the clinical data given as text with the graphical format.
Ma et al. used laser capture microdissection to analyse ELF5
expression in tumor and patient-associated adjacent normal
epithelium. Data are expressed as fold change in expression and
is colored according to ER and PR status. Grade 3 tumors are
indicated by asterisks.
(TIF)
Figure S2 ELF5 expression in breast cancer. Each row
shows the results from a study referenced by Oncomine. Total
numbers of tumors are indicated including type, lobular (LBC), or
ductal (DBC). Cell color indicates average fold change (see scale)
in ELF5 expression for the indicated phenotypic comparison
contained within each cell. p-Values are given where ,0.05.
(TIF)
Figure S3 Construction and validation of an inducible
ELF5-V5 expression system in MCF7 and T47D breast
cancer cell lines. (A) the retroviral expression vector was
constructed as indicated using the Genentech pHUSH ProEX
vector. Addition of DOX relives repression of cytomeglovirus
promoter (CMV)-driven expression of ELF5 tagged by V5, by
binding the tetracycline repressor (TetR) and removing it from the
Tet operon (TO). TetR expression is linked to Puromycin
resistance (PURO) via an internal ribosome entry site (IRES)
ensuring coexpression of these activities. Control cells were
Figure 8. Elevated ELF5 allows escape from antiestrogen-induced proliferative arrest. (A) Affymetrix profiling of the expression (red high,
green low) of key estrogen response genes in two models of antiestrogen resistance. The lines were derived from MCF7 cells from the Cardiff
laboratory (MCF7C) to be resistant to TAMR or FASR. Additional two heat maps show the change in the expression of the ELF5 transcriptional
signature in TAMR and FASR cells compared to parental. (B) PCR validation of the change in ELF5 expression in TAMR and FASR cells. (C) Drug-
response signatures from Oncomine enriched among genes implicated in antiestrogen resistance that are ELF5 ChIP targets. (D) Eduction in ELF5
expression by estrogen treatment in MCF7C and TAMR cells. (E) Effects of ELF5 knockdown in TAMR cells on the expansion in cell number. Insets,
demonstration of ELF5 knockdown by qPCR and IHC compared to both risc-free and scrambled siRNA controls. (F) BrdU labeling shows ELF5
knockdown inhibits cell proliferation in TAMR cells to a much greater extent than seen in the parental cells. (G) Model of ELF5 action in normal
development and breast cancer, see the Discussion for details.
doi:10.1371/journal.pbio.1001461.g008
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constructed using this vector without the ELF5-V5 cassette. (B)
Quantification of ELF5 isoforms in T47D and MCF7 cells. qPCR
specific to each isoform was used to compare expression levels.
Amplification efficiency was very similar for both assays. Left-hand
side panel, ESE2B was expressed at levels more than three orders
of magnitude greater than ESE2A. Right-hand panel shows
relative ESE2A expression. (C) Induction of ELF5-V5 expression
increases the mRNA level of its direct transcriptional target, whey
acidic protein (Wap) compared to an empty vector control plasmid,
in HC11 mouse mammary epithelial cells. Cells were treated from
day 4 by the lactogenic hormones prolactin, insulin and
hydrocortisone.
(TIF)
Figure S4 Visualization of the transcriptional functions
of ELF5 in breast cancer. GSEA-identified signatures
indicative of function within expression profiles derived from
forced ELF5 expression in T47D and MCF7 luminal breast cancer
cells. Results are visualized using the enrichment map plug-in for
Cytoscape. Each node is a gene set, diameter indicates size, outer
node color represents the magnitude and direction of enrichment
(see scale) in T47D cells, inner node color enrichment in MCF7
cells. Thickness of the edges (green lines) is proportional the
similarity of linked nodes. The most related clusters are placed
nearest to each other. View the PDF at 800% or 1,600% to
explore the network in detail.
(PDF)
Figure S5 Visualization of the transcriptional functions
of ELF5 in breast cancer cell cycle and cancer gene set
sub network in T47D and MCF7 cells. Inset, the region of
the complete network from Figure S4 that is highlighted in red and
yellow is expanded here. Main panel, nodes, and edges forming
the cell cycle and cancer-related network, as explained in the key
and legend of Figure S4.
(TIF)
Figure S6 Visualization of the transcriptional functions
of ELF5 in breast cancer molecular subtype network in
T47D and MCF7 cells. Inset, the region of the complete
network from Figure S4 highlighted in red and yellow is expanded
here. Main panel, nodes, and edges forming the molecular subtype
network as explained in the key and legend of Figure S4.
(TIF)
Figure S7 Heat maps of leading edge genes contained
within the cell cycle cluster in T47D cells. Gene expression
is high (dark red), middle (white), or low (purple) in row-
normalized depictions of gene expression levels. First two columns
from the left are duplicates –DOX then next two are duplicates
+DOX. Labels indicate gene set name.
(TIF)
Figure S8 Heat maps of leading edge genes contained
within the Cytoscape cancer cluster in T47D cells. Gene
expression is high (dark red), middle (white), or low (purple) in row-
normalized depictions of expression levels. First two columns from
the left are duplicates –DOX then next two are duplicates +DOX.
Labels indicate gene set name.
(TIF)
Figure S9 Heat maps of leading edge genes contained
within the Cytoscape breast cancer subtype cluster in
T47D or MCF7 cells. Gene expression is high (dark red), middle
(white), or low (purple) in row-normalized depictions of expression
levels. First two columns from the left are duplicates –DOX then
next two are duplicates +DOX. Labels indicate cell model and
gene set name.
(TIF)
Figure S10 Heat maps of leading edge genes contained
within the Cytoscape breast cancer estrogen response
cluster in T47D cells. Gene expression is high (dark red),
middle (white), or low (purple) in row-normalized depictions of
expression levels. First two columns from the left are duplicates –
DOX then next two are duplicates +DOX. Labels indicate gene
set name.
(TIF)
Figure S11 Visualization of the transcriptional func-
tions of ELF5 in luminal A breast cancers. GSEA identified
signatures indicative of function within an expression profile
derived by correlation of gene expression with ELF5 expression in
luminal A breast cancers from the UNC337 series using Pearson
correlation. Results are visualized using the enrichment map plug-
in for Cytoscape. Each node is a gene set, diameter indicates size,
node color represents the magnitude and direction of enrichment.
Thickness of the edges (green lines) is proportional to the similarity
of linked nodes. The most related clusters are placed nearest to
each other. View the PDF at 800% or 1,600% to explore the
network in detail.
(PDF)
Figure S12 ELF5 modulates breast cancer cell accumu-
lation. (A) Effects of DOX addition on cell number at 0 h (+D
0 h, closed circles), or at 24 h (+D24 h, closed circles), or at 48 h
(+D48 h, closed circles), or not added (2D, open circles). Inset,
comparison of the level of exogenous ELF5-V5 induction by DOX
with that effected by treatment with the progestin R5020 on
endogenous ELF5. (B) Effect of DOX withdrawal on cell number.
Cells carrying the ELF5-V5 cassette were plated with DOX
(+D0 h, closed circles) and remained on DOX or were withdrawn
from DOX (+D0 h 2D24 h, open circles) after 24 h. Inset decay
in ELF5-V5 expression by Western blot. (C) T47D-ELF5-V5 cells
were grown with (+D) or without (2D) DOX on agar gels for
3 wk. Colony numbers from pooled cells or a clonal line are
shown. (D) T47D (circles, dashed lines) or MCF7 cells (squares,
solid lines) were transfected with siRNA against ELF5 mRNA
(siELF5, solid symbols), or a RISC-complex inactive control
siRNA (risc, open symbols). Inset, The degree of ELF5 mRNA
knockdown was measured by qPCR at 72 h. (E and F)
quantification of Western blots in Figure 5D, showing the effects
of ELF5-V5 induction on cell adhesion molecules.
(TIF)
Figure S13 ELF5 modulates cell proliferation. (A) T47D-
V5 and MCF7-V5 cells were treated with DOX for 48 h. DNA
was labeled by BrdU incorporation for 2 h and analysed by flow
cytometry using propidium iodide to measure total DNA content.
BrdU incorporation (y axis) and DNA content (x axis) distinguish
G0–G1, S, and G2-M phases of the cell cycle, with phase
distribution expressed as a percentage of total cells (*p,0.05,
**p,0.005). (B) Changes in the expression of the indicated key cell
cycle regulatory genes with time measured by Western blot. (C)
Changes in the expression of the indicated cell cycle regulatory
genes with time measured by qPCR. (D) Flow cytometric profiles
of hydroxyl urea arrested cells released into cycle, from which the
data in Figure 4H were derived. (E) Quantification of Figure 4F,
changes in cell cycle regulatory proteins occurring following the
release of hydroxyl urea arrested cells.
(TIF)
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Figure S14 Expression of the ELF5 transcriptional
signature in breast cancer. (A) hypergeometric interaction
between 943 genes repressed (DN) or 966 genes induced (UP) by
forced expression of ELF5-V5 in T47D cells, or 785 ELF5 ChIP
targets in T47D, with a 641 gene proliferation signature. (B) Left-
hand side heat map shows the expression change in response to the
induction of ELF5-V5 in T47D cells of the 55 ELF5 ChIP targets
involved in proliferation that were identified in (A). Right-hand
side heat map shows the expression of the 55 ELF5 ChIp targets in
the Desmedt breast cancer series. p-Values and fold change (FC)
for genes is shown where significant differential expression was
observed between ER2 and ER+ cancers. (C) Breast cancer series
in Oncomine showing significant enrichment of the 55 ELF5 ChIP
targets. (D) Heat maps showing the expression change of estrogen
induced (E2 I) or repressed (E2 R) genes in response to forced
ELF5-V5 expression (+D). Annotations at the side are examples of
enriched gene sets with p values. T = T47D, M = MCF7. (E) Heat
maps illustrating examples of differential expression of the ELF5
ChIP targets in relation to prognostic indicators within some of the
breast cancer series indicated in Figure 5E by asterisks.
(TIF)
Figure S15 The ELF5 transcriptional signature correct-
ly distinguishes breast cancer subtype. An ELF5 transcrip-
tional signature was defined as ELF5 ChIP targets with robust
changes in expression in response to forced ELF5 expression in
T47D cells. It was used to predict ER status (A) or breast cancer
subtype (B) in the Reyal series. Rows of the confusion matrix show
percent correct subtype prediction at the shaded cells and the
distribution of confused predictions by subtype across the row. (C)
Ability of this ELF5 transcriptional signature to predict breast
cancer subtype and clinical characteristics in the NKI295 series.
The 55 Elf5 gene signature was used to cluster the NKI295 series.
Subtypes assigned to this series by its authors are colored as
indicated. Heat map shows gene expression levels with enriched
gene sets within the major gene clusters listed along side. Bottom
panel shows associated clinical correlates with the significance of
each colored bar indicated by the text at the right. Generally good
outcomes are in yellow, poor outcomes in purple or red.
(TIF)
Figure S16 Visualization of the transcriptional func-
tions of ELF5 in breast and mammary cancer. GSEA-
identified signatures indicative of function within expression
profiles derived from forced ELF5 expression in T47D luminal
breast cancer cells and knockdown of ELF5 function in HCC1937
basal breast cancer cells. Results are visualized using the
enrichment map plug-in for Cytoscape. Each node is a gene set,
diameter indicates size, outer node color represents the magnitude
and direction of enrichment (see scale) in HCC1937 cells, inner
node color enrichment in T47D cells. Thickness of the edges
(green lines) is proportional the similarity of linked nodes. The
most related clusters are placed nearest to each other. The
functions of prominent clusters are shown.
(TIF)
Figure S17 ELF5 specifies breast cancer subtype. GSEA
network derived from forced ELF5 expression in T47D luminal
breast cancer cells (inner node color) and knockdown of ELF5
expression in HCC1937 basal breast cancer cells (outer node
color). Node size is proportional to gene set size, thicker green lines
indicate greater leading edge gene overlap. Nodes are positioned
according to similarity in leading edge genes. Labels indicate the
functional significance of the four clusters generated.
(TIF)
Table S1 ELF5 ChIP targets and expression changes in
T47D-ELF5-V5 cells. Spreadsheet showing the ELF5 ChIP
targets and their changed levels of expression in response to forced
ELF5-V5 expression in T47D cells.
(XLSX)
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